A tumor in the brain means major challenges – for the patient and for healthcare. In addition, it may be difficult to reach making surgery difficult. Passing various nerve centers that control important functions of the body is critical. Supplementary treatment with chemotherapy and radiation is generally needed.
When using laser ablation in neurosurgery, so-called laser interstitial thermal therapy (LITT), a region of interest is directly targeted and treated with high precision. Areas in the brain, not accessible for open surgery, can be treated as LITT is typically minimally invasive through use of MRI guidance (MRgLITT), and a stereotactic access system.
In collaboration with partners and through clinical programs, CLS is expanding into MRgLITT for treatment of patients with tumors and other lesions in the brain, including epileptogenic foci.
A system for MRI guided laser ablation in neurosurgery is cleared by the US Food and Drug Administration (FDA) as of September 22, 2022. It is commercialized by our partner ClearPoint Neuro Inc. under the brand name ClearPoint Prism™ Neuro Laser Therapy System, starting in the USA.
The new system includes CLS’s:
A clinical study at Skåne University Hospital, Lund , evaluating safety and feasibility using the CLS system for MRgLITT in minimally invasive ablation of lesions in the brain, such as primary tumors of patients diagnosed with glioblastoma, is now recruiting patients.
Glioblastoma is the most aggressive brain tumor and almost incurable. Despite intensive research and drug development the treatment of this disease remains a challenge. Hence, the need for new treatment options to offer affected patients is huge.
Our goal is to develop the field of therapy – by offering tools for precise and cost-efficient treatment.
Both abstracts provide the latest insights into the clinical use of focal laser ablation for prostate cancer, contributing to the ongoing development of minimally invasive cancer therapies.
On the 29th of August, CLS organized a training camp for our European distributors within urology and their Clinical Applications Specialists. During two intense days in Turin, Italy, the team learned a lot about the treatment of localized prostate cancer using the CLS TRANBERG® product portfolio, both in theory and in practice.
Now, when summer is approaching and we're all looking forward to enjoying some days off, it's time to sumarize the news from the first half of 2024.
Welcome to Clinical Laserthermia Systems.
Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!
Please choose your country or region
